World

FDA approves new innovative drug for pancreatic cancer

The FDA has authorized the pill daraxonrasib, providing a new treatment option for metastatic pancreatic cancer.

27 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: FDA approves new innovative drug for pancreatic cancer — Archive photoPhoto: MBq at German Wikipedia · Wikimedia Commons · Public domain

The U.S. Food and Drug Administration (FDA) has approved a new drug, daraxonrasib, for the treatment of the most common type of pancreatic cancer, one of the deadliest forms of the disease. This innovative pill aims to offer a more effective option for patients living with this serious condition.

Daraxonrasib works by blocking a mutated protein that contributes to tumor growth in over 90% of pancreatic cancer cases. This drug has undergone several clinical trials, showing promising results, including nearly doubling the average survival time of patients compared to conventional chemotherapy.

The new treatment is specifically intended for adults with metastatic pancreatic cancer who have already undergone prior treatment or who cannot undergo combined chemotherapy. The FDA granted accelerated approval for the drug, reflecting its importance in the fight against this serious illness.

The approval of daraxonrasib brings hope to many patients with advanced-stage cancer, who have limited therapeutic options available. CBS News medical correspondent Dr. Céline Gounder highlighted the potential of the drug to extend patients’ lives.

The medication, also known as Rasonque in some sources, was analyzed in rigorous clinical trials before receiving this approval. Results indicate that it may provide a significant alternative for those whose cancer has already spread throughout the body, potentially altering the treatment course.

The authorization of this new drug represents a significant development in the treatment of pancreatic cancer, a considerable medical challenge. This new therapeutic option is now available to patients in the U.S., who hope for substantial benefits from its use.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.